703 / 1631
First-line treatment options recommended by NCCN or ESMO
1,2
*NCCN guideline recommendation only (category 2b); rituximab alone may be considered if low tumour burden
2
1L, first line;; chemo, chemotherapy CHOP, cyclophosphamide, vincristine, doxorubicin
and prednisone/prednisolone; CVP, cyclophosphamide, vincristine and prednisone/prednisolone; FL, follicular
lymphoma; PFS, progression-free survival; R, rituximab
1. Dreyling M,
et al. Ann Oncol
2016; 27(Suppl. 5):v83–v90;
2. NCCN Guidelines. B-cell Lymphomas. Version 2.2017;
3. Jacobson CA, Freedman AS.
Lancet
2013; 381:1163–1165;
Symptomatic
1L FL
1,2
R-CHOP
R-B
R-CVP
R
2
Rituximab maintenance
NCCN only (2b)
Alternative option*
Phase 3 Study
3,4,5
N
Median Follow
up, mos (range)
Estimated 3-
year PFS (%)
Hiddemann, 2005 (GLSG)
CHOP
R-CHOP
205
223
18 (1–38)
18 (1–38)
50
75
Salles, 2011 (PRIMA)
R-chemo + observation
R-chemo + R maintenance
513
505
36 (IQR 30–42)
36 (IQR 30–42)
58
75
Hochster, 2009 (ECOG1496)
CVP + observation
CVP + R maintenance
113
115
44.4
44.4
33
64